(CHANT)Real World Study of Duvelisib in the Treatment of Non-Hodgkin's Lymphoma (NHL)
This is a multicenter, non-interventional and prospective real-world study to evaluate the efficacy and safety of Duvelisib capsules in patients with non-Hodgkin's lymphoma.
Follicular Lymphoma|Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma|Richter Syndrome|Marginal Zone Lymphoma|Peripheral T Cell Lymphoma|Diffuse Large B Cell Lymphoma
DRUG: Duvelisib
Adverse events (AE), The safety of the drug was evaluated by NCI-CTC AE 5.0 standard., From the first day of medication to 30 days after the last dose]
Overall Response Rate (ORR), Defined as the best response of complete response/remission (CR) or partial response/remission (PR)., up to 6 cycles of therapy (each cycle is 28 days)]|Duration of remission (DOR), Time from reaching CR or PR for the first time to disease progression., 4 year|Progression-Free-Survival (PFS), From date of inclusion to date of progression, relapse, or death from any cause., 4 year|Overall survival (OS), From the date of inclusion to date of death, irrespective of cause., 4 year|Quality of life (QOL), The quality of life scale, ranging from 0 to 100. A score of 0 represents the worst health and a score of 100 represents the best health., 4 year
This is a multicenter, non-interventional and prospective real-world study to evaluate the efficacy and safety of Duvelisib administered to subjects who have been diagnosed with non-Hodgkin's lymphoma that is relapsed or refractory, including but not limited to the following subtypes : a) Follicular lymphoma(FL); b) Chronic lymphocytic leukemia/small lymphocytic lymphoma or Richter syndrome(CLL/SLL or RS); c) Marginal zone lymphoma(MZL); d) Peripheral T-cell lymphoma(PTCL); e) Diffuse large B-cell lymphoma(DLBCL).